Business Description
Caliway Biopharmaceuticals Co Ltd
ISIN : TW0006919004
Total Employee Number:
41Description
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 37.49 | |||||
Equity-to-Asset | 0.98 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.48 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 415.83 | |||||
Beneish M-Score | 699.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.5 | |||||
3-Year EBITDA Growth Rate | 2.1 | |||||
3-Year EPS without NRI Growth Rate | 2 | |||||
3-Year FCF Growth Rate | -9.4 | |||||
3-Year Book Growth Rate | 47.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.46 | |||||
9-Day RSI | 37.83 | |||||
14-Day RSI | 42.52 | |||||
3-1 Month Momentum % | 5.61 | |||||
6-1 Month Momentum % | -37.08 | |||||
12-1 Month Momentum % | -45.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 60.03 | |||||
Quick Ratio | 59.96 | |||||
Cash Ratio | 57.87 | |||||
Days Inventory | 198.51 | |||||
Days Sales Outstanding | 25.91 | |||||
Days Payable | 42.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.1 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.3 | |||||
Operating Margin % | -2827.47 | |||||
Net Margin % | -877.11 | |||||
EBITDA Margin % | -770.11 | |||||
FCF Margin % | -1025.9 | |||||
OCF Margin % | -955.98 | |||||
ROE % | -2.76 | |||||
ROA % | -2.72 | |||||
ROIC % | -23.77 | |||||
3-Year ROIIC % | -8.68 | |||||
ROC (Joel Greenblatt) % | -212.51 | |||||
ROCE % | -2.74 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 42.2 | |||||
PS Ratio | 5242.11 | |||||
PB Ratio | 16.84 | |||||
Price-to-Tangible-Book | 16.82 | |||||
EV-to-EBIT | -586.87 | |||||
EV-to-EBITDA | -667.39 | |||||
EV-to-Revenue | 5139.6 | |||||
EV-to-FCF | -500.98 | |||||
Price-to-GF-Value | 1.69 | |||||
| Price-to-Net-Current-Asset-Value | 39.06 | |||||
| Price-to-Net-Cash | 40.49 | |||||
Earnings Yield (Greenblatt) % | -0.17 | |||||
FCF Yield % | -0.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Caliway Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 29.393 | ||
| EPS (TTM) (NT$) | -0.17 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.78 | ||
| 3-Year Sortino Ratio | 1.43 | ||
| Volatility % | 88.66 | ||
| 14-Day RSI | 42.52 | ||
| 14-Day ATR (NT$) | 5.821403 | ||
| 20-Day SMA (NT$) | 106.63 | ||
| 12-1 Month Momentum % | -45.67 | ||
| 52-Week Range (NT$) | 75.1 - 277 | ||
| Shares Outstanding (Mil) | 1,556.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Caliway Biopharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Caliway Biopharmaceuticals Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| 10:1 Stock Split | 2025-07-14 | 121.50 (+2.10%) |
Show
Entries
Caliway Biopharmaceuticals Co Ltd Frequently Asked Questions
What is Caliway Biopharmaceuticals Co Ltd(TPE:6919)'s stock price today?
The current price of TPE:6919 is NT$99.60. The 52 week high of TPE:6919 is NT$277.00 and 52 week low is NT$75.10.
When is next earnings date of Caliway Biopharmaceuticals Co Ltd(TPE:6919)?
The next earnings date of Caliway Biopharmaceuticals Co Ltd(TPE:6919) is .
Does Caliway Biopharmaceuticals Co Ltd(TPE:6919) pay dividends? If so, how much?
Caliway Biopharmaceuticals Co Ltd(TPE:6919) does not pay dividend.
Press Release
Articles on Caliway Biopharmaceuticals Co Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers